You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Hormone Receptor/Growth Factor Receptor-Negative Breast Cancer

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Breast Cancer, Invasive Breast Cancer, Unresectable Breast Carcinoma Trial in Boston (Onvansertib, Paclitaxel)

Recruiting
  • Breast Cancer
  • +9 more
  • Boston, Massachusetts
  • +2 more
Oct 25, 2022

Hormone Receptor Positive HER-2 Negative Breast Cancer Trial in Shanghai (Docetaxel, Carboplatin, Epirubicin)

Recruiting
  • Hormone Receptor Positive HER-2 Negative Breast Cancer
  • Shanghai, Shanghai, China
    Breast cancer institute of Fudan University Cancer Hospital
Jun 12, 2023

Metastatic Breast Cancer, Locally Advanced Breast Cancer, Breast Cancer Trial in Ocala (Samuraciclib, Fulvestrant)

Recruiting
  • Metastatic Breast Cancer
  • +2 more
  • Ocala, Florida
    Ocala Oncology Center PL DBA Florida Cancer Affiliates
Jul 19, 2023

Locally Advanced or Unresectable Metastatic Breast Cancer, Stage IV Breast Cancer Trial in Marietta, East Brunswick (Sacituzumab

Recruiting
  • Locally Advanced or Unresectable Metastatic Breast Cancer
  • Stage IV Breast Cancer
  • Sacituzumab Govitecan-hziy
  • +3 more
  • Marietta, Georgia
  • +1 more
Apr 21, 2023

HR+/HER2- Advanced Breast Cancer, Targeted Therapy Trial in Beijing (Everolimus, Chidamide, Endocrine therapy)

Recruiting
  • HR+/HER2- Advanced Breast Cancer
  • Targeted Therapy
  • Beijing, Beijing, China
    National Cancer Center/National Clinical Research Center for Can
Aug 1, 2023

Hepatocellular Carcinoma, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancers Trial (ABBV-400)

Not yet recruiting
  • Hepatocellular Carcinoma
  • +6 more
  • (no location specified)
Oct 10, 2023

Breast Cancer Stage II Trial in Xi'an (Anlotinib)

Recruiting
  • Breast Cancer Stage II
  • Xi'an, Shannxi Province, China
    Xijing Hospital Affiliated to Air Force Military Medical Univers
Sep 25, 2022

Metastatic Breast Cancer Trial in Spain (Pembrolizumab, Paclitaxel)

Active, not recruiting
  • Metastatic Breast Cancer
  • Hospitalet de Llobregat, Barcelona, Spain
  • +6 more
Jan 23, 2023

Breast Cancer, Breast Cancer Metastatic, Hormone Receptor Positive Tumor Trial (INX-315)

Not yet recruiting
  • Breast Cancer
  • +8 more
  • (no location specified)
Feb 9, 2023

Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, HER2-Negative Breast Carcinoma Trial in

Not yet recruiting
  • Anatomic Stage II Breast Cancer AJCC v8
  • +3 more
  • Biospecimen Collection
  • +7 more
  • Portland, Oregon
    SWOG
Sep 27, 2023

HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients Trial (PERT-IJS plus trastuzumab,

Not yet recruiting
  • HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients
  • PERT-IJS plus trastuzumab, carboplatin and docetaxel
  • Perjeta plus trastuzumab, carboplatin and docetaxel
  • (no location specified)
Sep 21, 2023

Metastatic Breast Cancer Trial in Zhengzhou (Famitinib, SHR6390, Fulvestrant)

Recruiting
  • Metastatic Breast Cancer
  • Zhengzhou, Henan, China
    Henan Cancer Hospital
Jan 25, 2022

Breast Cancer, Chemo Effect Trial (Capecitabine)

Not yet recruiting
  • Breast Cancer
  • Chemotherapy Effect
  • (no location specified)
Mar 9, 2022

Breast Cancer Trial in Shanghai (HS-10352 combined with fulvestrant (Stage 1), HS-10352 combined with fulvestrant (Stage 2))

Recruiting
  • Breast Cancer
  • HS-10352 combined with fulvestrant (Stage 1)
  • HS-10352 combined with fulvestrant (Stage 2)
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Aug 15, 2022

Among Patients Receiving Palbociclib Combinations for Hormone

Recruiting
  • Breast Neoplasms
  • Palbociclib plus an aromatase inhibitor
  • Palbociclib plus fulvestrant
  • Doha, Qatar
    Hamad Medical Corporation
Nov 18, 2021

HR-positive,HER2-negative in Advanced Breast Cancer Trial in Beijing (TQB3616 capsules, TQB3616-matching , Fluvestrin injection)

Recruiting
  • HR-positive,HER2-negative in Advanced Breast Cancer
  • TQB3616 capsules
  • +2 more
  • Beijing, Beijing, China
  • +1 more
May 11, 2022

A NIS of Alpelisib in Combination With Fulvestrant in

Not yet recruiting
  • Hormone Receptor Positive HER2 Negative Breast Cancer With a PIK3CA Mutation
  • Alpelisib
  • Fulvestrant
  • (no location specified)
Aug 9, 2022

Breast Cancer, Invasive Breast Cancer Trial in Milwaukee (Anastrozole, Letrozole, Exemestane)

Active, not recruiting
  • Breast Cancer
  • Invasive Breast Cancer
  • Milwaukee, Wisconsin
    Froedtert Hospital
Sep 16, 2021

Breast Cancer Trial in Egypt

Completed
  • Breast Cancer
    • Alexandria, Egypt
    • +7 more
    Jan 24, 2022

    Breast Cancer Trial in Port Saint Lucie (RGT-419B, RGT-419B in combination with hormonal therapy)

    Recruiting
    • Breast Cancer
    • RGT-419B
    • RGT-419B in combination with hormonal therapy
    • Port Saint Lucie, Florida
      Hem-Onc Associates of the Treasure Coast
    Apr 18, 2022

    Advanced Solid Tumor, Gynecologic Cancer, Breast Cancer Trial in United States (PY314, Combination Therapy: PY314 +

    Recruiting
    • Advanced Solid Tumor
    • +8 more
    • PY314
    • Combination Therapy: PY314 + Pembrolizumab
    • Scottsdale, Arizona
    • +12 more
    Mar 28, 2022

    Among Hormone Receptor-positive/Human Epidermal Growth Factor

    Recruiting
    • Breast Cancer
      • Tokyo, Japan
        Pfizer Japan Inc.
      Nov 29, 2021

      Metastatic Breast Cancer, Triple Negative Breast Cancer, Hormone Receptor Positive Tumor Trial in Indianapolis, Winston-Salem

      Recruiting
      • Metastatic Breast Cancer
      • +2 more
      • Indianapolis, Indiana
      • +1 more
      Sep 28, 2021

      Breast Tumors, Tumor Metastasis Trial in India (Abemaciclib, Nonsteroidal Aromatase Inhibitor (NSAI), Fulvestrant)

      Recruiting
      • Breast Neoplasms
      • Neoplasm Metastasis
      • Hyderabad, Andhra Pradesh, India
      • +15 more
      Aug 8, 2022

      Metastatic Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Hormone Receptor Positive Breast Cancer

      Recruiting
      • Metastatic Breast Cancer
      • +2 more
      • Washington, District of Columbia
        Lombardi Comprehensive Cancer Center
      Jan 17, 2022